Latest Interventional cardiology Stories

University of Washington Leads All SynCardia Certified Centers with 10 Implants of the Total Artificial Heart in 2012

2012-12-06 12:26:49

TUCSON, Ariz., Dec. 6, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University of Washington (UW) Medical Center in Seattle has performed 10 implants of the SynCardia temporary Total Artificial Heart so far in 2012, the most of any SynCardia Certified Center this year. It also marks a new record for number of implants performed by a...

HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast

2012-12-06 08:27:56

FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 23(rd )Annual Healthcare Conference at 10:00 a.m. EST on Thursday, December 13, 2012. The conference is being held December 12-13 at the...

InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting

2012-12-04 04:21:56

TEL-AVIV, Israel, December 4, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) Embolic Protection Stent (EPS), will sponsor a satellite symposium on December 4th at the ICI, Innovations in Cardiovascular Innovation, Meeting at the David Intercontinental Hotel, Tel-Aviv. InspireMD's symposium will be chaired by Dr. Gregg W. Stone, and the meeting faculty includes Drs. Martin Leon, Sigmund Silber and Chaim...

The Christ Hospital On Cutting Edge Of New Stent Technology; Implants Investigational New Device

2012-12-03 12:27:28

Global Trial Led by Dr. Dean Kereiakes of Lindner Research Center CINCINNATI, Dec. 3, 2012 /PRNewswire-USNewswire/ -- Clinical scientists at The Christ Hospital's Lindner Research Center are leading a worldwide study evaluating new breakthrough coronary stent technology that may make stenting easier and safer. The first procedures to implant the novel SYNERGYâ"¢ stent were performed at The Christ Hospital by Drs. Thomas Broderick and Joseph Choo, interventional cardiologists....

First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY(TM) Coronary Stent System Featuring a Bioabsorbable Polymer Coating

2012-11-30 08:24:17

NATICK, Mass., Nov. 30, 2012 /PRNewswire/ -- The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the SYNERGY( )Stent System and support U.S. Food and Drug Administration and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions. Boston Scientific received CE Mark approval for the SYNERGY Stent System last month. The EVOLVE II...

Thoratec Announces $150 Million Share Repurchase Authorization

2012-11-26 08:24:46

PLEASANTON, Calif., Nov. 26, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of up to $150 million of the company's shares of common stock. The company's prior authorization expired in early November. As part of the new authorization, the company has entered into a $75 million...

HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart Failure

2012-11-20 16:28:41

FRAMINGHAM, Mass. and SYDNEY, Nov. 20, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare(®) Ventricular Assist System as a bridge to heart transplantation in patients with...

XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease

2012-11-20 12:28:00

AUSTIN, Texas, Nov. 20, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study in patients receiving MABp1 to reduce restenosis after percutaneous revascularization of the Superficial Femoral Artery (SFA). Patients receiving MABp1 demonstrated a 58 percent reduction in Major Adverse Cardiovascular Events (MACE) and 60 percent longer patency in treated vessels compared to control patients. This...

Angiotech partner Cook Medical receives FDA approval for its Zilver PTX Paclitaxel-eluting peripheral stent

2012-11-16 20:21:22

VANCOUVER, Nov. 16, 2012 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced that its partner Cook Medical, Inc. ("Cook") received approval on November 15, 2012 from the U.S. Food and Drug Administration ("FDA") to market and sell the proprietary Zilver® PTX® drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. Zilver PTX is the first drug-eluting...

InspireMD Postpones $40 Million Registered

2012-11-16 08:24:07

TEL AVIV, Israel, November 16, 2012 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") announced that, based on recent adverse market conditions, it has chosen to postpone its planned registered public offering of $40 million worth of its shares of common stock until a later date. InspireMD's registration statement on Form S-1, as filed with the Securities and Exchange Commission, has not been withdrawn and the Company expects to continue to evaluate the...